Search for "SEC Live Filings Digest" to find out more.
Aradigm Corporation (ARDM) announced its financial results for the fourth quarter and full fiscal year 2013, reporting quarterly earnings that neared profitability. Quarterly revenue topped $4.6M, up from $223K a year ago but operating expenses increased as well, from $2.4M to $4.9M, attributed mostly to research and development. The company nearly broke even in fourth quarter with a net loss of $0.7M and $0.00 per share, an improvement from a net loss of $2.5M and $0.01 per share a year ago. For the full fiscal year, revenues jumped from $1.0M to $9.7M while operating expenses jumped from $7.7M to $29.6M. Annual earnings resulted in a wider net loss of $21.6M and $0.06 per share from last year’s net loss of $8.2M and $0.04 per share. The specialty pharmaceutical company’s President and CEO Igor Gonda remarked that the year was a pivotal year with clinical trials progressing, sales increasing, and further research on preventing and treating severe respiratory diseases.